{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:43:14Z","timestamp":1793666594146,"version":"4.5.1"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2021,7,1]]},"DOI":"10.1001\/jamaneurol.2021.0249","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:30:35Z","timestamp":1615807835000},"page":"864","source":"Crossref","is-referenced-by-count":157,"title":["Encephalitis Induced by Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"78","author":[{"given":"Roser","family":"Velasco","sequence":"first","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, l\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Aut\u00f2noma de Barcelona, Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Villagr\u00e1n","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain"},{"name":"Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jov\u00e9","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sim\u00f3","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, l\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Vilari\u00f1o","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, l\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Thoracic Oncology Unit, Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alemany","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, l\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Palmero","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Mart\u00ednez-Villacampa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruna","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Unit, Hospital Universitari de Bellvitge-Institut Catal\u00e0 d Oncologia L\u2019Hospitalet, Institut d\u00b4Investigaci\u00f3 Biom\u00e8dica de Bellvitge, l\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Aut\u00f2noma de Barcelona, Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"nrv210001r1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.v25.2","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials.","volume":"25","author":"Bruna","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"nrv210001r2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis.","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"},{"issue":"9","key":"nrv210001r3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"nrv210001r4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.v88.1","article-title":"Value of onconeural antibodies in checkpoint inhibitor\u2013related toxicities.","volume":"88","author":"Vogrig","year":"2020","journal-title":"Ann Neurol"},{"issue":"7","key":"nrv210001r5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors.","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"nrv210001r6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.v87.5","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum.","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"issue":"4","key":"nrv210001r7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis.","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"8","key":"nrv210001r8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes.","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"nrv210001r9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti\u2013contactin-associated protein\u2013like 2 antibody secondary to pembrolizumab therapy.","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"1","key":"nrv210001r10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/10428194.2019.1658104","article-title":"Checkpoint inhibitor\u2013induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma.","volume":"61","author":"Thummalapalli","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"nrv210001r11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab.","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"nrv210001r12","article-title":"Ipilimumab induced encephalitis: a case report.","volume":"11","year":"2015","journal-title":"Immunome Res"},{"issue":"6","key":"nrv210001r13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2326-6066.CIR-15-0035","article-title":"Ipilimumab-induced encephalopathy with a reversible splenial lesion.","volume":"3","author":"Conry","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"nrv210001r14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2017.09.026","article-title":"Immune checkpoint inhibitor\u2013associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: a new entity of drug-induced autoimmune encephalitis?","volume":"87","author":"Strik","year":"2017","journal-title":"Eur J Cancer"},{"key":"nrv210001r15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2020.03.006","article-title":"Encephalitis related to immunotherapy for lung cancer: analysis of a multicenter cohort.","volume":"143","author":"Sanchis-Borja","year":"2020","journal-title":"Lung Cancer"},{"issue":"12","key":"nrv210001r16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with nivolumab for melanoma.","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"nrv210001r17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2217\/imt-2016-0058","article-title":"Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.","volume":"8","author":"Choe","year":"2016","journal-title":"Immunotherapy"},{"issue":"5","key":"nrv210001r18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-018-0363-6","article-title":"Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin\u2019s disease.","volume":"54","author":"De la Hoz","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"nrv210001r19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5692\/clinicalneurol.cn-001218","article-title":"A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer.","volume":"59","author":"Yonenobu","year":"2019","journal-title":"Rinsho Shinkeigaku"},{"issue":"4","key":"nrv210001r20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","article-title":"Immune checkpoint inhibitor induced anti\u2013glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange.","volume":"267","author":"Chung","year":"2020","journal-title":"J Neurol"},{"issue":"6","key":"nrv210001r21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/10428194.2020.1725508","article-title":"Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma.","volume":"61","author":"Erol-Yildiz","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"nrv210001r22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors.","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neurooncol"},{"issue":"2","key":"nrv210001r23","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor\u2013induced limbic encephalitis.","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"nrv210001r24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/CJI.0000000000000314","article-title":"Paraneoplastic encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy.","volume":"43","author":"Kang","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"nrv210001r25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","article-title":"Anti-Hu\u2013associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor\u2013responsive myxoid chondrosarcoma.","volume":"23","author":"Papadopoulos","year":"2018","journal-title":"Oncologist"},{"key":"nrv210001r26","article-title":"Limbic encephalitis following immunotherapy against metastatic malignant melanoma.","volume":"2016","author":"Salam","year":"2016","journal-title":"BMJ Case Rep"},{"key":"nrv210001r27","article-title":"Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma.","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep Neurol Med"},{"issue":"6","key":"nrv210001r28","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1177\/1078155220904147","article-title":"Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: a case report.","volume":"26","author":"Taillefer","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"nrv210001r29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer.","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"nrv210001r30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A case series of PD-1 inhibitor\u2013associated paraneoplastic neurologic syndromes.","volume":"334","author":"Gill","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"1","key":"nrv210001r31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ccr3.v8.1","article-title":"Neurotoxicities associated with checkpoint inhibitors: two case reports and a review of the literature.","volume":"8","author":"Cordes","year":"2019","journal-title":"Clin Case Rep"},{"key":"nrv210001r32","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.2147\/OTT","article-title":"Pancytopenia and limbic encephalopathy complicating immunotherapy for clear cell endometrial cancer with microsatellite instability-high (MSI-H).","volume":"12","author":"Kanbour","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"3","key":"nrv210001r33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/practneurol-2019-002464","article-title":"Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy.","volume":"20","author":"Lyons","year":"2020","journal-title":"Pract Neurol"},{"issue":"8","key":"nrv210001r34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jjco\/hyz087","article-title":"Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody\u2013positive patient.","volume":"49","author":"Shibaki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"nrv210001r35","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.2169\/internalmedicine.8895-17","article-title":"Acute cerebellar ataxia induced by nivolumab.","volume":"56","author":"Kawamura","year":"2017","journal-title":"Intern Med"},{"issue":"9","key":"nrv210001r36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/CJI.0000000000000228","article-title":"Ipilimumab\/nivolumab-related opsoclonus-myoclonus-ataxia syndrome variant in a patient with malignant pleural mesothelioma.","volume":"41","author":"Maller","year":"2018","journal-title":"J Immunother"},{"issue":"10","key":"nrv210001r37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s10072-018-3465-4","article-title":"Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.","volume":"39","author":"Naito","year":"2018","journal-title":"Neurol Sci"},{"issue":"1","key":"nrv210001r38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2017.12.001","article-title":"Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy.","volume":"2","author":"Zurko","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"1","key":"nrv210001r39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep"},{"issue":"3","key":"nrv210001r40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/1078155215572932","article-title":"Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature.","volume":"22","author":"Abdallah","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"nrv210001r41","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung.","volume":"19","author":"Matsuoka","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"nrv210001r42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis.","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"nrv210001r43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000477162","article-title":"PD-1 checkpoint inhibitor associated autoimmune encephalitis.","volume":"10","author":"Schneider","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"6","key":"nrv210001r44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MAJ.0000000000000584","article-title":"Meningoencephalitis following ipilimumab administration in metastatic melanoma.","volume":"350","author":"Stein","year":"2015","journal-title":"Am J Med Sci"},{"issue":"7","key":"nrv210001r45","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti\u2013PD-1 therapy.","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"key":"nrv210001r46","article-title":"Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature.","volume":"6","author":"Laserna","year":"2018","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"nrv210001r47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3988\/jcn.2019.15.2.259","article-title":"Immune-checkpoint-inhibitor\u2013induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin.","volume":"15","author":"Kim","year":"2019","journal-title":"J Clin Neurol"},{"issue":"5","key":"nrv210001r48","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/j.cllc.2020.03.006","article-title":"Immune-related encephalitis in two patients treated with immune checkpoint inhibitor.","volume":"21","author":"Robert","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"nrv210001r49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2018.00108","article-title":"Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature.","volume":"9","author":"Leitinger","year":"2018","journal-title":"Front Immunol"},{"issue":"1-2","key":"nrv210001r50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3121\/cmr.2019.1417","article-title":"Nivolumab-associated acute demyelinating encephalitis: a case report and literature review.","volume":"17","author":"Zafar","year":"2019","journal-title":"Clin Med Res"},{"issue":"2","key":"nrv210001r51","first-page":"267","article-title":"Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.","volume":"10","author":"Niki","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"19","key":"nrv210001r52","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.2169\/internalmedicine.2537-18","article-title":"Elevated adenosine deaminase levels in the cerebrospinal fluid in immune checkpoint inhibitor\u2013induced autoimmune encephalitis.","volume":"58","author":"Fujiwara","year":"2019","journal-title":"Intern Med"},{"issue":"9","key":"nrv210001r53","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/annonc\/mdx252","article-title":"Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.","volume":"28","author":"Ito","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"nrv210001r54","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1111\/jdv.v33.12","article-title":"Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.","volume":"33","author":"Galmiche","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"nrv210001r55","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes.","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"nrv210001r56","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"S2","key":"nrv210001r57","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1111\/jns.v24.S2","article-title":"Immune checkpoint inhibitors\u2013induced neuromuscular toxicity: from pathogenesis to treatment.","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2777621\/jamaneurology_velasco_2021_rv_210001_1624467410.9432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T19:56:47Z","timestamp":1625774207000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2777621"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}